109 related articles for article (PubMed ID: 16079931)
1. Valsartan, an angiotensin II type-I receptor blocker, and left ventricular diastolic function--a case report.
Okura Y; Nakashima Y; Tojo H; Tashiro E; Saku K
Angiology; 2005; 56(4):467-73. PubMed ID: 16079931
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Crespo MJ; Cangiano JL; Altieri PI; Escobales N
J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
[TBL] [Abstract][Full Text] [Related]
3. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
Poulsen SH
Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
Jugdutt BI; Menon V
J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):217-26. PubMed ID: 14506547
[TBL] [Abstract][Full Text] [Related]
6. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2003 Jun; 44(6):884-90. PubMed ID: 12791814
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Mizuta Y; Kai H; Mizoguchi M; Osada K; Tahara N; Nakaura H; Kuwahara F; Imaizumi T;
Hypertens Res; 2008 Oct; 31(10):1835-42. PubMed ID: 19015589
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
Janardhanan R; Daley WL; Naqvi TZ; Mulvagh SL; Aurigemma G; Zile M; Arnold JM; Artis E; Purkayastha D; Thomas JD; Solomon SD;
Am Heart J; 2006 Aug; 152(2):246-52. PubMed ID: 16875904
[TBL] [Abstract][Full Text] [Related]
9. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
[TBL] [Abstract][Full Text] [Related]
10. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
Tsutsui H; Matsushima S; Kinugawa S; Ide T; Inoue N; Ohta Y; Yokota T; Hamaguchi S; Sunagawa K
Hypertens Res; 2007 May; 30(5):439-49. PubMed ID: 17587756
[TBL] [Abstract][Full Text] [Related]
12. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
13. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
14. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
15. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
16. [Effects of benazepril combined with valsartan on congestive heart failure].
Ye JF; Liu DS
Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1441-2, 1447. PubMed ID: 16305977
[TBL] [Abstract][Full Text] [Related]
17. Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Croom KF; Keating GM
Am J Cardiovasc Drugs; 2004; 4(6):395-404. PubMed ID: 15554725
[TBL] [Abstract][Full Text] [Related]
18. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Biala A; Finckenberg P; Korpi A; Loytainen M; Martonen E; Levijoki J; Mervaala E
J Physiol Pharmacol; 2011 Jun; 62(3):275-85. PubMed ID: 21893687
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
Yamamoto S; Hayashi N; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
